Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Steven Eliot Come, M.D.

TitleAssociate Professor of Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Med Ctr
Hematology/Oncology, CC 913
330 Brookline Ave
Boston MA 02215
Phone617/667-4599
Fax617/667-9919

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):1061-6.
    View in: PubMed
  2. Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011 Sep; 10(5):819-26.
    View in: PubMed
  3. Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 May 15; 17(10):3490-9.
    View in: PubMed
  4. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8.
    View in: PubMed
  5. Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
    View in: PubMed
  6. Stadler ZK, Come SE. Review of gene-expression profiling and its clinical use in breast cancer. Crit Rev Oncol Hematol. 2009 Jan; 69(1):1-11.
    View in: PubMed
  7. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
    View in: PubMed
  8. Farag N, Burns R, Come SE. Update: a 62-year-old woman with a new diagnosis of breast cancer. JAMA. 2008 Mar 5; 299(9):1055-6.
    View in: PubMed
  9. Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 1; 112(3 Suppl):673-8.
    View in: PubMed
  10. Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
    View in: PubMed
  11. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
    View in: PubMed
  12. Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61.
    View in: PubMed
  13. Come SE. A 62-year-old woman with a new diagnosis of breast cancer. JAMA. 2006 Mar 22; 295(12):1434-42.
    View in: PubMed
  14. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 1; 12(3 Pt 2):997s-1000s.
    View in: PubMed
  15. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
    View in: PubMed
  16. Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15; 104(2):236-9.
    View in: PubMed
  17. Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer. 2005 Apr; 6 Suppl 1:S15-22.
    View in: PubMed
  18. Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005 Mar 20; 23(9):1934-40.
    View in: PubMed
  19. Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005 Feb; 41(3):346-56.
    View in: PubMed
  20. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s.
    View in: PubMed
  21. Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer. 2004 Apr 1; 100(7):1358-64.
    View in: PubMed
  22. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 1; 10(1 Pt 2):327S-330S.
    View in: PubMed
  23. Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet. 2004; 43(8):529-38.
    View in: PubMed
  24. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38.
    View in: PubMed
  25. Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S.
    View in: PubMed
  26. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
    View in: PubMed
  27. Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
    View in: PubMed
  28. Dubey A, Recht A, Come SE, Gelman RS, Silver B, Harris JR, Shulman LN. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 1999 Nov 1; 45(4):877-84.
    View in: PubMed
  29. Hardenbergh PH, Recht A, Gollamudi S, Come SE, Hayes DF, Shulman LN, O'Neill A, Gelman RS, Silver B, Harris JR. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1999 Aug 1; 45(1):69-72.
    View in: PubMed
  30. Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, Silver B, Nixon A, Harris JR, Schnitt SJ, Connolly JL. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer. 1998 Dec 15; 83(12):2502-8.
    View in: PubMed
  31. Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, Monson JM, Silver B, Harris JR, Connolly JL. Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol. 1998 Feb; 16(2):480-6.
    View in: PubMed
  32. Dubey AK, Recht A, Come S, Shulman L, Harris J. Why and how to combine chemotherapy and radiation therapy in breast cancer patients. Recent Results Cancer Res. 1998; 152:247-54.
    View in: PubMed
  33. Wong JS, Recht A, Beard CJ, Busse PM, Cady B, Chaffey JT, Come S, Fam S, Kaelin C, Lingos TI, Nixon AJ, Shulman LN, Troyan S, Silver B, Harris JR. Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys. 1997 Nov 1; 39(4):915-20.
    View in: PubMed
  34. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996 May 23; 334(21):1356-61.
    View in: PubMed
  35. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996 May 1; 87(9):3625-32.
    View in: PubMed
  36. Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, Silver B, Weinstein H, Come S, Canellos GP, Coleman CN. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995 May-Jun; 1(1):33-42.
    View in: PubMed
  37. Mauch PM, Canellos GP, Shulman LN, Silver B, Tarbell NJ, Come S, Rabin MS, Coleman CN. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. J Clin Oncol. 1995 Apr; 13(4):947-52.
    View in: PubMed
  38. Recht A, Harris JR, Come SE. Sequencing of irradiation and chemotherapy for early-stage breast cancer. Oncology (Williston Park). 1994 Mar; 8(3):19-28; discussion 28, 31-2, 37.
    View in: PubMed
  39. Uematsu M, Bornstein BA, Recht A, Abner A, Come SE, Shulman LN, Silver B, Harris JR. Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 2; 25(5):765-70.
    View in: PubMed
  40. Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1993 Jan; 11(1):44-8.
    View in: PubMed
  41. Recht A, Come SE, Harris JR. Integration of Conservative Surgery, Radiotherapy, and Chemotherapy for Patients With Early-Stage Breast Cancer. Semin Radiat Oncol. 1992 Apr; 2(2):107-115.
    View in: PubMed
  42. Recht A, Come SE, Gelman RS, Goldstein M, Tishler S, Gore SM, Abner AL, Vicini FA, Silver B, Connolly JL, et al. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol. 1991 Sep; 9(9):1662-7.
    View in: PubMed
  43. Abner AL, Recht A, Vicini FA, Silver B, Hayes D, Come S, Harris JR. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys. 1991 Jul; 21(2):331-8.
    View in: PubMed
  44. Wheeler CA, Shulman LN, Ervin T, Come SE, Schnipper LE. Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung. Cancer. 1991 Feb 15; 67(4):892-5.
    View in: PubMed
  45. Eng C, Skolnick AE, Come SE. Elevated creatine kinase and malignancy. Hosp Pract (Off Ed). 1990 Dec 15; 25(12):123, 126, 129-30.
    View in: PubMed
  46. Harris JR, Recht A, Connolly J, Cady B, Come S, Henderson IC, Koufman C, Love S, Schnitt S, Osteen R. Conservative surgery and radiotherapy for early breast cancer. Cancer. 1990 Sep 15; 66(6 Suppl):1427-38.
    View in: PubMed
  47. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990 Apr; 8(4):648-56.
    View in: PubMed
  48. Rose MA, Henderson IC, Gelman R, Boyages J, Gore SM, Come S, Silver B, Recht A, Connolly JL, Schnitt SJ, et al. Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):711-7.
    View in: PubMed
  49. Safian RD, Come SE, Kadin M, Lorell BH. Use of pulmonary capillary wedge aspirates for the antemortem diagnosis of pulmonary microvascular tumor. Cathet Cardiovasc Diagn. 1989 Jun; 17(2):112-5.
    View in: PubMed
  50. Recht A, Schnitt SJ, Connolly JL, Rose MA, Silver B, Come S, Henderson IC, Slavin S, Harris JR. Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. Int J Radiat Oncol Biol Phys. 1989 Jan; 16(1):3-9.
    View in: PubMed
  51. Sheldon T, Hayes DF, Cady B, Parker L, Osteen R, Silver B, Recht A, Come S, Henderson IC, Harris JR. Primary radiation therapy for locally advanced breast cancer. Cancer. 1987 Sep 15; 60(6):1219-25.
    View in: PubMed
  52. Henderson IC, Hayes DF, Come S, Harris JR, Canellos G. New agents and new medical treatments for advanced breast cancer. Semin Oncol. 1987 Mar; 14(1):34-64.
    View in: PubMed
  53. Lion J, Henderson M, Malbon A, Bergman A, Come S. Case mix and charges for inpatient and outpatient chemotherapy. Health Care Financ Rev. 1987; 8(4):65-71.
    View in: PubMed
  54. Recht A, Connolly JL, Schnitt SJ, Cady B, Love S, Osteen RT, Patterson WB, Shirley R, Silen W, Come S, et al. Conservative surgery and radiation therapy for early breast cancer: results, controversies, and unsolved problems. Semin Oncol. 1986 Dec; 13(4):434-49.
    View in: PubMed
  55. Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov; 4(11):1592-7.
    View in: PubMed
  56. Rosen EM, Goldberg ID, Rose C, Come S, Goldstein M, Simon L, Botnick LE. Sequential multi-agent chemotherapy and whole abdominal irradiation for stage III ovarian carcinoma. Radiother Oncol. 1986 Nov; 7(3):223-31.
    View in: PubMed
  57. Mauch P, Leonard R, Skarin A, Rosenthal D, Come S, Chaffey J, Hellman S, Canellos G. Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol. 1985 Oct; 3(10):1301-8.
    View in: PubMed
  58. Mauch P, Goffman T, Rosenthal DS, Canellos GP, Come SE, Hellman S. Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol. 1985 Sep; 3(9):1166-73.
    View in: PubMed
  59. Gargan TJ, Come SE, Satwicz PR. Breast cancer chemotherapy: perioperative considerations in breast reconstruction. Plast Reconstr Surg. 1985 Mar; 75(3):430-4.
    View in: PubMed
  60. Come PC, Come SE, Riley MF, Carl LV, Nakao S. Reversible right ventricular outflow tract compression by immunoblastic sarcoma. Am J Cardiol. 1985 Jan 1; 55(1):239-40.
    View in: PubMed
  61. Harris JR, Recht A, Schnitt S, Connolly J, Silver B, Come S, Henderson IC. Current status of conservative surgery and radiotherapy as primary local treatment for early carcinoma of the breast. Breast Cancer Res Treat. 1985; 5(3):245-55.
    View in: PubMed
  62. Beadle GF, Come S, Henderson IC, Silver B, Hellman S, Harris JR. The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1984 Nov; 10(11):2131-7.
    View in: PubMed
  63. Kaplan WD, Come SE, Takvorian RW, Laffin SM, Gelman RS, Weiss GR, Garnick MB. Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion. J Clin Oncol. 1984 Nov; 2(11):1266-9.
    View in: PubMed
  64. Canellos GP, Come SE, Skarin AT. Chemotherapy in the treatment of Hodgkin's disease. Semin Hematol. 1983 Jan; 20(1):1-24.
    View in: PubMed
  65. Come PC, Come SE, Hawley CR, Gwon N, Riley MF. Echocardiographic manifestations of carcinoid heart disease. J Clin Ultrasound. 1982 May-Jun; 10(5):233-7.
    View in: PubMed
  66. Kuribayashi S, Phillips DA, Harrington DP, Bettmann MA, Garnic JD, Come SE, Levin DC. Therapeutic embolization of the gastroduodenal artery in hepatic artery infusion chemotherapy. AJR Am J Roentgenol. 1981 Dec; 137(6):1169-72.
    View in: PubMed
  67. Frei E, Garnick MB, Ensminger WD, Israel M, Steele GD, Kaplan WD, Come SE. Biochemical pharmacology in medical oncology. Cancer Treat Rep. 1981; 65 Suppl 3:21-6.
    View in: PubMed
  68. Kutz I, Borysenko JZ, Come SE, Benson H. Paradoxical emetic response to antiemetic treatment in cancer patients. N Engl J Med. 1980 Dec 18; 303(25):1480.
    View in: PubMed
  69. Come SE, Jaffe ES, Andersen JC, Mann RB, Johnson BL, DeVita VT, Young RC. Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations. Am J Med. 1980 Nov; 69(5):667-74.
    View in: PubMed
  70. Pesando JM, Come SE, Stark J, Parker LM, Griffiths CT, Canellos GP. cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1147-8.
    View in: PubMed
  71. Brown E, Freedman S, Arbeit R, Come S. Invasive pulmonary aspergillosis in an apparently nonimmunocompromised host. Am J Med. 1980 Oct; 69(4):624-7.
    View in: PubMed
  72. Schnipper LE, Come SE. Adjuvant chemotherapy for breast cancer. Compr Ther. 1980 Oct; 6(10):42-7.
    View in: PubMed
  73. Kaplan WD, Ensminger WD, Come SE, Smith EH, D'Orsi CJ, Levin DC, Takvorian RW, Steele GD. Radionuclide angiography to predict patient response to hepatic artery chemotherapy. Cancer Treat Rep. 1980; 64(12):1217-22.
    View in: PubMed
  74. Come SE, Chabner BA. Staging in non-Hodgkin's lymphoma: approach, results and relationship to histopathology. Clin Haematol. 1979 Oct; 8(3):645-56.
    View in: PubMed
  75. Greenberger JS, Come SE, Weichselbaum RR. Issues of controversy in radiation therapy and combined modality approaches to Hodgkin's disease. Clin Haematol. 1979 Oct; 8(3):611-24.
    View in: PubMed
  76. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, Steele G, Frei E. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978 Nov; 38(11 Pt 1):3784-92.
    View in: PubMed
  77. Ensminger WD, Thompson M, Come S, Egan EM. Hepatic arterial BCNU: a pilot clinical-pharmacologic study in patients with liver tumors. Cancer Treat Rep. 1978 Oct; 62(10):1509-12.
    View in: PubMed
  78. Eastman RC, Come SE, Strewler GJ, Gorden P, Kahn CR. Adriamycin therapy for advanced insulinoma. J Clin Endocrinol Metab. 1977 Jan; 44(1):142-8.
    View in: PubMed
  79. Come SE, Shohet SB, Robinson SH. Surface remodeling vs. whole-cell hemolysis of reticulocytes produced with erythroid stimulation or iron deficiency anemia. Blood. 1974 Dec; 44(6):817-30.
    View in: PubMed
  80. Come SE, Shohet SB, Robinson SH. Surface remodelling of reticulocytes produced in response to erythroid stress. Nat New Biol. 1972 Apr 5; 236(66):157-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Come's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_